Elastofibroma dorsi: Clinicopathologic review of 6 cases

Baystate Medical Center, Springfield, Massachusetts, United States
The Annals of thoracic surgery (Impact Factor: 3.65). 06/2007; 83(5):1894-7. DOI: 10.1016/j.athoracsur.2006.11.050
Source: PubMed

ABSTRACT Elastofibroma dorsi is a rare, benign lesion arising from connective tissue and usually found at the angle of the scapula. Surgical resection is often indicated in the presence of an enlarging mass or when malignancy can not be excluded. Herein we report our most recent case of elastofibroma dorsi and our review of 6 cases from the past 16 years.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Elastofibroma dorsi (ED) is a tumor that develops in the space between the lower angle of the scapula and the posterior thoracic wall. Due to the rarity of this type of tumor, the number of reported consecutive series is limited. Surgical excision, usually recommended for symptomatic cases to confirm diagnosis and relieve symptoms, has been associated with a high complication rate. To analyze the clinical characteristics and outcomes of surgical treatment, we retrospectively reviewed 20 consecutive cases of surgically resected ED. Of the 20 patients, 14 (70%) exhibited preoperative symptoms associated with the tumor. The mean diameter of the resected tumors averaged 72 mm (range, 45-110 mm). The surgical outcomes were satisfactory, except for the development of hematoma or seroma in 9 cases (43%), 8 of which achieved a complete resolution with conservative treatment. Age, hypertension, the presence of preoperative tumor-related symptoms and intraoperative bleeding were not found to be significantly associated with the incidence of hematoma. However, tumor diameter and the duration of postoperative drainage were significantly associated with occurrence of hematoma (P=0.02 and P=0.01, respectively). Surgical resection should only be recommended for symptomatic patients, due to the high incidence of postoperative complications. To prevent the development of postoperative hematoma or seroma, careful observation of the wound, with suction drainage for >7 days and additional surgical procedures to facilitate adhesion of the wound margins, are recommended.
    Molecular and Clinical Oncology 05/2014; 2(3):421-424. DOI:10.3892/mco.2014.257
  • [Show abstract] [Hide abstract]
    ABSTRACT: Elastofibroma dorsi (ED) is a rare, benign lesion arising from connective tissue, usually found at the inferior pole of the scapula. To date, only a few small series have been reported in the English literature and there are few data about the long-term outcomes after surgery. Our goal is to contribute a better understanding of this tumour and to determine the long-term outcomes after surgery. Sixteen patients with a diagnosis of ED were identified from the unit's database. The clinical presentation, diagnosis, pathological evidences and long-term outcomes were evaluated. There were 11 females and 5 males with a mean age of 61.1 years (range 38-78 years). The tumour was located on the right in 5 (31.2%) patients, on the left in 6 (37.5%) patients and bilaterally in 5 (31.2%). Six patients had painful scapular swelling resulting in restriction of movement of the shoulder whereas 10 reported only painful scapular mass. All 16 patients underwent complete resections. The tumour size ranged from 3 to 15 cm. The mean hospital stay was 3.1 ± 1.4 days with a morbidity of 18.75% (seroma observed in 3 patients). The mean follow-up was 58.4 ± 29.5 months (range 11-92 months). In 2 patients (12.5%) a new occurrence on the contralateral side was observed at the follow-up. Elastofibroma dorsi is a rare, ill-defined, pseudotumoural lesion of the soft tissues. Surgical treatment can be proposed if the lesion is symptomatic. Furthermore, at the follow-up, the possibility of new occurrences on the contralateral side should be kept in mind.
    Interactive Cardiovascular and Thoracic Surgery 11/2013; 18(2). DOI:10.1093/icvts/ivt442 · 1.11 Impact Factor
  • Value in Health 05/2005; 8(3):362-362. DOI:10.1016/S1098-3015(10)62967-1 · 2.89 Impact Factor